Sysmex (OTCMKTS:SSMXY) Issues FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 0.370-0.370 for the period, compared to the consensus earnings per share estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Wall Street Analysts Forecast Growth

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a report on Monday, March 16th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold”.

Sysmex Stock Up 3.2%

Shares of OTCMKTS:SSMXY opened at $8.38 on Friday. The firm’s 50 day moving average price is $8.72 and its 200 day moving average price is $9.39. The stock has a market cap of $5.28 billion, a price-to-earnings ratio of 22.05 and a beta of 1.10. Sysmex has a fifty-two week low of $8.12 and a fifty-two week high of $18.10. The company has a quick ratio of 2.44, a current ratio of 3.33 and a debt-to-equity ratio of 0.12.

Sysmex (OTCMKTS:SSMXY) last issued its earnings results on Thursday, May 14th. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.02). The firm had revenue of $877.92 million during the quarter, compared to analyst estimates of $862.45 million. Sysmex had a net margin of 7.13% and a return on equity of 7.28%. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. As a group, equities research analysts predict that Sysmex will post 0.5 earnings per share for the current fiscal year.

About Sysmex

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan?based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high?speed, high?volume testing for blood cell counts and differential analysis.